Orforglipron Based on 2 publication(s) in Google Scholar Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-like peptide-1 receptor ( GLP-1R ), which exhibits potency in ameliorates the type 2 diabete
The treatment of polycystic ovarian syndrome with diet Dietary treatment for PCOS has become a cornerstone of managing the condition, addressing the metabolic and hormonal imbalances that are hallmarks of the disorder
Int J Odontostomat 15:922927 Verma P, Naik S, Nanda P, Banerjee S, Naik S, Ghosh A (2019) In vitro anticancer activity of virgin coconut oil and its fractions in liver and oral cancer cells
Continue through active healing phase (typically 8-12 weeks) potentially extending into remodeling phase (months) for complete recovery
Nasal administration technique Using PT-141 nasal spray: Blow nose gently (clear passages) Prime pump (1-2 test sprays into air) Tilt head slightly forward (not back) Insert nozzle into nostril (don't deep) Spray while breathing in gently 2-3 sprays per nostril typically Alternate nostrils Avoid sniffing hard (keeps in nasal tissue) Wait 2-3 minutes between sprays Absorption through nasal mucosa: PT-141 absorbed across nasal lining Enters bloodstream directly Bypasses stomach/liver (like injection) But: Lower bioavailability (~30%) Hence need 2-3x higher dose Nasal spray pros/cons: When to choose nasal: Needle phobic Value convenience highly Don't mind using 2-3x more peptide Want slightly faster onset Traveling (easier to transport) When to choose injection: Want cost efficiency Comfortable with injections Prefer guaranteed absorption Limited PT-141 supply Already using other injectable peptides Managing PT-141 side effects Minimizing nausea and other reactions
This content does not constitute a recommendation for or against any medication or telehealth platform
